Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00071136
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2003-10-13
Brief Title:
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer NSCLC
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Phase 12 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer The primary goal is to find out if the tumor gets smaller or disappears with this treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-US-JMGC | None | None | None |